PMID- 26703273
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 112
DP  - 2016 Feb
TI  - Progression to treatment failure among Chinese patients with type 2 diabetes 
      initiated on metformin versus sulphonylurea monotherapy--The Hong Kong Diabetes 
      Registry.
PG  - 57-64
LID - S0168-8227(15)00459-3 [pii]
LID - 10.1016/j.diabres.2015.11.003 [doi]
AB  - AIMS: To assess the development of treatment failure in Chinese patients with 
      type 2 diabetes mellitus (T2DM) initiated on metformin or sulphonylurea (SU) 
      monotherapy, with consideration of various potential sources of biases. METHODS: 
      A 1:1-matched new metformin and SU user cohort on immortal time and mean 
      propensity score after multiple imputation was selected from a cohort of 5889 
      Chinese patients with T2DM. Treatment failure was defined as progression to (i) 
      combination oral anti-hyperglycemia drug therapy, (ii) insulin use, or (iii) a 
      treatment haemoglobin A1c (HbA1c) >7.5% (58 mmol/mol). Stratified Cox regression 
      analysis on the matched pairs was employed to examine the associations between 
      initial monotherapy and onset of treatment failure. RESULTS: Of 554 new metformin 
      and 840 new SU users, 380 were matched. During a median follow-up duration of 3 
      years, 173 (45.6%) metformin users and 220 (57.9%) SU users experienced treatment 
      failure (annual failure rates of 15% and 19%, respectively). The median time from 
      monotherapy starting to treatment failure was 3.0 [inter-quartile range (IQR): 
      1.8-5.4] years for metformin users, versus 1.8 (IQR: 0.9-4.1) years for SU users 
      (p<0.001). Stratified Cox regression analysis showed significantly lower risk of 
      treatment failure for metformin users (HR [95% CI], 0.62[0.47-0.81]; p<0.001). 
      Consistent results were found in analyses based on traditional adjustment schemes 
      with or without imputation. CONCLUSIONS: By systematically incorporating new-user 
      design, multiple imputation and matching methods, we found that Chinese patients 
      with T2DM initiated on metformin monotherapy were associated with a significant 
      delay in the onset of treatment failure compared to SU monotherapy.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Jiang, Guozhi
AU  - Jiang G
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Luk, Andrea O
AU  - Luk AO
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Yang, Xilin
AU  - Yang X
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Tianjin 
      Medical University, Tianjin, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Tam, Claudia H T
AU  - Tam CHT
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Lau, Siu Him
AU  - Lau SH
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Ozaki, Risa
AU  - Ozaki R
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Kong, Alice P S
AU  - Kong APS
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese 
      University of Hong Kong, Hong Kong, Hong Kong; Li Ka Shing Institute of Health 
      Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
FAU - Tong, Peter C
AU  - Tong PC
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Chow, Chun Chung
AU  - Chow CC
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong.
FAU - Chan, Juliana C N
AU  - Chan JCN
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese 
      University of Hong Kong, Hong Kong, Hong Kong; Li Ka Shing Institute of Health 
      Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
FAU - So, Wing Yee
AU  - So WY
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong. Electronic address: wingyeeso@cuhk.edu.hk.
FAU - Ma, Ronald C W
AU  - Ma RCW
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese 
      University of Hong Kong, Hong Kong, Hong Kong; Li Ka Shing Institute of Health 
      Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong. Electronic 
      address: rcwma@cuhk.edu.hk.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20151123
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/metabolism
MH  - Hong Kong/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Outpatients
MH  - Propensity Score
MH  - *Registries
MH  - Sulfonylurea Compounds/*administration & dosage
MH  - Time Factors
MH  - Treatment Failure
OTO - NOTNLM
OT  - Diabetes
OT  - Drug use bias
OT  - Metformin
OT  - Sulphonylurea
OT  - Treatment failure
EDAT- 2015/12/26 06:00
MHDA- 2016/10/07 06:00
CRDT- 2015/12/26 06:00
PHST- 2015/08/03 00:00 [received]
PHST- 2015/10/07 00:00 [revised]
PHST- 2015/11/09 00:00 [accepted]
PHST- 2015/12/26 06:00 [entrez]
PHST- 2015/12/26 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
AID - S0168-8227(15)00459-3 [pii]
AID - 10.1016/j.diabres.2015.11.003 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2016 Feb;112:57-64. doi: 10.1016/j.diabres.2015.11.003. 
      Epub 2015 Nov 23.